Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Bristol-Myers Squibb
New York Medical College
Mayo Clinic